2018 Fiscal Year Final Research Report

Therapeutic development for pancreatic cancer via cancer specific glucose metabolism

Research Project

PDF

Project/Area Number	16K10604
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Digestive surgery
Research Institution	Kumamoto University
Principal Investigator	HASHIMOTO Daisuke 熊本大学, 医学部附属病院, 助教 (80508507)
Co-Investigator(Kenkyū-buntansha)	澤山浩熊本大学, 医学部附属病院, 非常勤診療医師 (40594875) 今井克憲熊本大学, 大学院生命科学研究部(医), 助教 (60555746) 東孝暁熊本大学, 医学部附属病院, 非常勤診療医師 (70594878)
Project Period (FY)	2016-04-01 – 2019-03-31
Keywords	膵臓外科学 / 癌糖代謝
Outline of Final Research Achievements	The diagnosis of malignant diseases has been determined using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Glucose transporter type 1 (Glut-1) is a key protein associated with the accumulation of FDG in cancer cells. In this study the expression of Glut-1 and the corrected maximum standardized uptake value (cSUVmax) of FDG-PET were examined in 138 surgically resected pancreatic cancers. Glut-1 was positive in 69 patients. The median relapse-free and overall survival times were significantly shorter in the Glut-1-positive group (11 vs. 22 months, respectively) than in the Glut-1-negative group (23 vs. 42 months, respectively). The cSUVmax was significantly associated with long-term survival. The relapse free and overall survival rates were significantly poorer in the high-cSUVmax group than in the low-cSUVmax group. Glut-1 expression was associated with cSUVmax accumulation. In the multivariate analysis, high cSUVmax was identified as an independent prognostic factor.
Free Research Field	膵癌、胆道癌の基礎研究と臨床研究、診断、手術や化学療法を含めた集学的治療。
Academic Significance and Societal Importance of the Research Achievements	膵癌は多くの症例で発見時既に切除不能である。また切除可能であっても、術後ほとんどの症例で再発をきたす難治性癌である。現在手術や抗がん剤による化学療法が治療の中心であるが、膵癌の更なる予後向上のために新しい治療法の開発は必要不可欠である。今回我々は癌細胞にグルコースを能動的に取り込むGlucose transporter 1: Glut1がある一定の膵癌患者の癌細胞の表面に多く発現していることを示した。Glut1の発現が多い症例はPET検査におけるFDGの集積も多く、また予後が悪いことが分かった。これは、Glut1をターゲットとした新しい分子標的治療の可能性を示すものである。